Valuation: Clene Inc.

Market Cap 53.59M 47.75M 43.79M 39.8M 74.81M 5.06B 76.52M 523M 210M 2.68B 201M 197M 8.49B P/E 2026 *
-1.46x
P/E 2027 * -2.21x
Enterprise Value 48.99M 43.65M 40.03M 36.38M 68.39M 4.63B 69.95M 478M 192M 2.45B 184M 180M 7.76B EV / Sales 2026 *
196x
EV / Sales 2027 * 2.38x
Free-Float
83.46%
Yield 2026 *
-
Yield 2027 * -
1 day+9.02%
1 week+1.74%
Current month+7.05%
1 month+4.86%
3 months-22.35%
6 months-49.32%
Current year-30.15%
1 week 3.6
Extreme 3.605
4.28
1 month 3.02
Extreme 3.0152
4.28
Current year 3.02
Extreme 3.0152
8.67
1 year 3.02
Extreme 3.0152
11.59
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
122.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/9/26 Free

Chief Executive Officer

15,244 0.1186%
16/9/26 Free

Chairman

434,451 3.3813%
16/9/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+9.02%+1.74%-62.45%-47.30% 53.59M
+10.00%+5.18%+54.35%+71.20% 60.57B
+1.44%+5.05%+22.52%+99.64% 55.51B
+3.32%+4.11%+14.82%+75.04% 55.22B
+1.48%-4.53%+26.28%+34.27% 43.27B
+7.19%+1.78%+22.90%+93.74% 40.36B
+3.24%+6.02%+241.62%+828.90% 41.63B
-3.79%-7.50%+89.46%+78.72% 33.29B
+5.32%+6.04%+20.27%+52.98% 32.27B
+3.71%+11.95%-40.60%+355.42% 22.91B
Average +4.15%+4.02%+38.92%+164.26% 38.51B
Weighted average by Cap. +3.94%+4.06%+52.40%+171.99%

Financials

2026 *2027 *
Net sales 249K 222K 204K 185K 348K 23.57M 356K 2.44M 977K 12.47M 936K 916K 39.52M 23.27M 20.73M 19.01M 17.28M 32.48M 2.2B 33.22M 227M 91.09M 1.16B 87.33M 85.46M 3.69B
Net income -34.49M -30.73M -28.18M -25.61M -48.15M -3.26B -49.25M -337M -135M -1.73B -129M -127M -5.46B -31M -27.62M -25.33M -23.02M -43.28M -2.93B -44.27M -303M -121M -1.55B -116M -114M -4.91B
Net Debt -4.6M -4.1M -3.76M -3.42M -6.42M -435M -6.57M -44.93M -18.01M -230M -17.27M -16.9M -729M 1.8M 1.6M 1.47M 1.34M 2.51M 170M 2.57M 17.58M 7.05M 90.03M 6.76M 6.61M 285M
Projected Income Statement - Annual - Clene Inc.
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
05/11/26 USD 4.100 +8.75% 88,749
03/11/26 USD 3.770 +4.43% 44,337
02/11/26 USD 3.610 -5.74% 54,014
30/10/26 USD 3.830 -1.79% 47,273
29/10/26 USD 3.900 -3.23% 34,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Clene Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.770USD
Average target price
32.20USD
Spread / Average Target
+754.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Clene Inc.
  1. Stock Market
  2. Stocks
  3. CLNN Stock